HRT / BHRT
HRT and BHRT restore declining estrogen and progesterone in perimenopausal and menopausal women, using standard or structurally identical hormone formulations delivered transdermally, orally, or via other routes. The modality has a well-documented and consequential evidence arc: the 2002 WHI trial triggered a global prescribing collapse, which subsequent re-analysis and the 2023 NICE guideline update substantially reversed for eligible women. In the longevity economy, HRT appears primarily through women-focused telehealth platforms and specialist menopause clinics. Evidence tier: well-evidenced.
What it is
Hormone replacement therapy (HRT) restores declining estrogen and progesterone levels in women experiencing perimenopause and menopause. Bioidentical HRT (BHRT) uses hormones that are structurally identical to those produced endogenously, typically synthesized from plant sources, as distinct from the conjugated equine estrogens used in earlier formulations. The clinical story of HRT is inseparable from one pivotal trial and its long correction arc. The Women's Health Initiative (WHI), published in 2002, reported elevated breast cancer risk in one arm of its combined estrogen-progestogen trial and triggered a sharp contraction in prescribing globally. Subsequent re-analysis through the 2010s, and a substantial revision of the risk picture in the 2017 WHI reinterpretation studies, established that the original findings had been substantially confounded by age: most participants were older and further from menopause onset than typical candidates for HRT. The 2023 NICE menopause guideline update, consistent with guidance from the British Menopause Society and the Menopause Society (formerly NAMS), now holds that for most women under 60 and within ten years of menopause onset, the benefits of HRT outweigh the risks. In the longevity economy, HRT and BHRT appear primarily through women-focused telehealth platforms and specialist menopause clinics, reflecting the modality's status as a durable, guideline-supported intervention for a specific and large patient population.
Who it is for
Women in perimenopause and menopause are the primary clinical population, particularly those experiencing vasomotor symptoms, sleep disruption, mood instability, cognitive changes, and accelerated bone loss. Current guidelines support use for most women under 60 and within ten years of menopause onset. The broader longevity framing also positions HRT as a tool for preserving bone mineral density, cardiovascular health, and metabolic function across the postmenopausal decades.
What to expect
HRT and BHRT are delivered across multiple formats depending on provider and formulation: oral tablets, transdermal patches, topical gels, skin sprays, vaginal inserts, and subcutaneous pellets. In the telehealth model prevalent among Atlas-listed entities, delivery typically begins with an intake assessment, a review of symptom history, and baseline bloodwork to establish hormone levels and screen for contraindications. A prescribing clinician then recommends a formulation and dose, followed by a follow-up appointment at 8 to 12 weeks to assess response and titrate. BHRT compounds are dispensed through specialty compounding pharmacies and are not FDA-approved as individual preparations, though the constituent hormones are regulated. Ongoing monitoring typically includes annual review of hormone levels, symptom response, and relevant risk markers. The Atlas entities associated with this modality are all women-focused telehealth platforms and clinic networks, reflecting the operational model dominant in this segment.
History and background
Estrogen therapy was first prescribed in the United States in the 1940s using conjugated equine estrogens (Premarin), with widespread adoption across the following decades for menopausal symptom management. Progestogen was added to protect the uterine lining after the 1970s finding that unopposed estrogen elevated endometrial cancer risk. By the 1990s, HRT was among the most commonly prescribed drugs in the US. The 2002 WHI trial publication triggered a collapse in prescribing that lasted more than a decade. Subsequent epidemiological re-analysis, most notably work by JoAnn Manson, one of the original WHI investigators, established that the trial population had been unrepresentative of typical clinical candidates, and that the risk-benefit picture differed substantially by age, timing of initiation, formulation, and route of administration. The decade-long reassessment culminated in the 2023 NICE guidelines and equivalent updates from major menopause societies globally, restoring HRT to a guideline-supported position for eligible women.
Worth knowing
The WHI's 2002 publication is estimated to have caused millions of women to discontinue HRT within months, an effect size in prescribing behavior rarely matched by a single trial. The subsequent recognition that this represented a flawed interpretation, not a definitive risk signal for typical candidates, is one of the more consequential course corrections in recent clinical guideline history. Transdermal estrogen delivery bypasses first-pass hepatic metabolism and is associated with a lower thrombotic risk profile than oral formulations, a distinction with direct clinical relevance for prescribing decisions. BHRT pellet implants, a niche delivery format, generate among the highest direct consumer interest in searches around menopause optimization, despite limited head-to-head evidence against other delivery routes.
Offered across the Atlas 6
Related modalities